“…However, the acquired drug resistance and systemic toxicity of CDDP severely compromise its anticancer effect, resulting in a poor prognosis [ [4] , [5] , [6] ]. Compared to CDDP, the platinum(IV) (Pt (IV), (c,c,t-[Pt(NH 3 ) 2 Cl 2 (OOCCH 2 CH 2 COOH) 2 )) prodrug with two axial ligands can specifically respond to tumor cells, which is converted into cytotoxic CDDP by excessive glutathione (GSH) in tumor cells, contributing to chemotherapy [ [7] , [8] , [9] ]. Despite its advantages, Pt (IV) prodrug still exhibits weak anticancer activity in suppressing tumor growth, limiting its clinical application [ 10 ].…”